ArticleEBioMedicine2017
Intratumor Heterogeneity in Primary Kidney Cancer Revealed by Metabolic Profiling of Multiple Spatially Separated Samples within Tumors.
Article in EBioMedicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 68 citations in OpenAlex.
- Tumour sampling conditions perturb the metabolic landscape of clear cell renal cell carcinoma.Nature communications · 2025Article
- Metabolites in the extracellular tumor microenvironment and the shaping of macrophage function.Molecular cell · 2025Review
- Impact of contrast enhancement phase on CT-based radiomics analysis for predicting post-surgical recurrence in renal cell carcinoma.Japanese journal of radiology · 2025Article
- Potential of Metabolic MRI to Address Unmet Clinical Needs in Localised Kidney Cancer.Cancers · 2025Review
- Disclosing the development and focus of sequencing and omics studies in kidney neoplasm research.Discover oncology · 2025Article
- K-Means Clustering of HyperpolarisedCancers · 2025Article
- Metabolomic characterisation of the glioblastoma invasive margin reveals a region-specific signature.Heliyon · 2025Article
- Metabolomic Analysis of Histological Composition Variability of High-Grade Serous Ovarian Cancer UsingInternational journal of molecular sciences · 2024Article
- Challenges of Spatially Resolved Metabolism in Cancer Research.Metabolites · 2024Review
- Metabolite profiling of human renal cell carcinoma reveals tissue-origin dominance in nutrient availability.eLife · 2024Article
- Signaling, cancer cell plasticity, and intratumor heterogeneity.Cell communication and signaling : CCS · 2024Article
- Metabolite profiling of human renal cell carcinoma reveals tissue-origin dominance in nutrient availability.bioRxiv : the preprint server for biology · 2024Article
- [Advances in Research on Cell Metabolic Interactions in the Tumor Microenvironment].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2024Review
- Plasma lipidomics profiling in predicting the chemo-immunotherapy response in advanced non-small cell lung cancer.Frontiers in oncology · 2024Article
- The immunometabolic ecosystem in cancer.Nature immunology · 2023Review
- Immunometabolic coevolution defines unique microenvironmental niches in ccRCC.Cell metabolism · 2023Article
- The expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma.Scientific reports · 2023Article
- Antibody-Based Therapeutics for the Treatment of Renal Cell Carcinoma: Challenges and Opportunities.The oncologist · 2023Review
- To metabolomics and beyond: a technological portfolio to investigate cancer metabolism.Signal transduction and targeted therapy · 2023Review
- Molecular signature of renal cell carcinoma by means of a multiplatform metabolomics analysis.Biochemistry and biophysics reports · 2022Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic alteration constitutes a hallmark of cancer. Glycolysis and antioxidant pathways in kidney cancer are elevated, with frequent mutation of the VHL gene. Intratumor genetic heterogeneity has been recently demonstrated in kidney cancer. However, intratumor metabolic heterogeneity has not been investigated. Here, we used global metabolomics analysis and tissue slice tracer studies to demonstrate that different portions of a human primary kidney tumor possess different metabolic characteristics and drug sensitivity. Pyruvate levels were elevated and pyruvate metabolism was altered in some tumor sections. These observations indicated that pyruvate metabolism may constitute a possible vulnerability of kidney cancer; indeed, pyruvate stimulated the growth of primary kidney cancer cells and pharmacological inhibition of pyruvate transporters slowed the growth of patient-derived kidney tumors in mice. These findings deepen our understanding of the intratumor metabolic heterogeneity of kidney cancer and may inform novel therapeutic approaches in human kidney cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.